Drug interactions involving antifungal drugs: Time course and clinical significance

Current Fungal Infection Reports

Volumn 4, Issue 2, 2010, Pages 103-110

  Bartell, Ashley ^a   Phatak, Arti ^a   Horn, Kirsten ^a   Postelnick, Michael ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Azoles; Drug interactions; Echinocandins; Polyenes

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ATORVASTATIN; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN; DIGOXIN; DOFETILIDE; EFAVIRENZ; FENTANYL; FLUCONAZOLE; FLUINDOSTATIN; ITRACONAZOLE; METHADONE; MICAFUNGIN; MIDAZOLAM; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; POSACONAZOLE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; SIMVASTATIN; TACROLIMUS; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; CRYPTOCOCCAL MENINGITIS; DRUG ANTAGONISM; DRUG ELIMINATION; DRUG INTERACTION; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; REVIEW; RHABDOMYOLYSIS; SYSTEMIC MYCOSIS; UNSPECIFIED SIDE EFFECT;

EID: 79952192750     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-010-0014-x     Document Type: Review

References (50)

1. Valeriote F, Medoff G, Tolen S, Dieckman J: Amphotericin B potentiation of the cytotoxicity of anticancer agents against both normal hematopoietic and leukemia cells in mice. J Natl Cancer Inst 1984, 73:475-482. (Pubitemid 14055230)
2. Valeriote F, Medoff G, Dieckman J: Potentiation of cytotoxicity of anticancer agents by several different polyene antibiotics. J Natl Cancer Inst 1984, 72:435-439. (Pubitemid 14198868)
3. Ozols RF, Hogan WM, Grotzinger KR, et al.: Effects of amphotericin B on Adriamycin and melphalan cytotoxicity in human and murine ovarian carcinoma and in L1210 leukemia. Cancer Res 1983, 43:959-964. (Pubitemid 13160003)
4. Valeriote F, Medoff G, Dieckman J: Potentiation of anticancer agent cytotoxicity against sensitive and resistant AKR leukemia by amphotericin B1. Cancer Res 1979, 39:2041-2045. (Pubitemid 9184997)
5. Saad AH, DePestel DD, Carver PL: Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006, 25:1730-1744. (Pubitemid 44885328)
6. Sugar AM, Saunders C, Idelson BA, Bernard DB: Interaction of fluconazole and cyclosporine. Ann Intern Med 1989, 110:844.
7. Diflucan [prescribing information]. New York, NY: Pfizer; 2008.
8. Blum RA, Wilton JH, Hilligoss DM, et al.: Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991, 49:420-425.
9. Tarumi Y, Perira, J, Watanabe S: Methadone and fluconazole: respiratory depression by drug interaction. J Pain Symptom Manage 2002, 23:286-298.
10. Cobb MN, Desai J, Brown LS, et al.: The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 1998, 63:655-662. (Pubitemid 28327893)
11. Panomvana Na, Ayudhya D, Thanompuangseree N, Tansubphaswadikul S: Effect of rifampin on the pharmacokinetics of fluconazole in patients with AIDS. Clin Pharmacokinet 2004, 43:725-732. (Pubitemid 39159002)
12. Shaukat A, Benekli M, Vladutiu GD, et al.: Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003, 56:24-29.
13. Kantola T, Backman JT, Niemi M, et al.: Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2005, 56:225-229.
14. Romero AJ, Le Pogamp P, Nilsson LG, Wood N: Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2005, 71:226-234.
15. VFEND, IV (voriconazole) for injection, VFEND, tablets (voriconazole), VFEND (voriconazole) for oral suspension [prescribing information]. New York, NY: Pfizer; 2008.
16. Venkataramanan R, Zang S, Gayowski T, Singh N: Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant and in human liver microsomes. Antimicrob Agents Chemother 2002, 46:3091-3093.
17. Purkins L, Wood N, Ghahramani P, et al.: Co-administration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003, 56:35-44.
18. Saari TI, Laine K, Neuvonen M, et al.: Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol 2008, 64:25-30.
19. Purkins L, Wood N, Kleinermans D, Nichols D: Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 2003, 56:24-29. (Pubitemid 37491730)
20. Nivoix Y, Ubeaud-Sequier G, Engel P, et al.: Drug-drug interaction of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab 2009, 10:395-409. This article summarizes azole drug interactions in patients with complicated medical histories. It assesses azole drug interactions in conditions such as HIV, cancer, and transplantation, and can help practitioners assess appropriate drug regimens for complicated patients.
21. Noxafil (posaconazole) suspension [package insert]. Kenilworth, NJ: Schering-Plough; 2008.
22. Krishna G, Parsons A, Kantesaria B, Mant T: Evaluation of the pharmacokinetics of posaconazole and rifabutin following coadministration to healthy men. Curr Med Res Opin 2007, 23:545-552. (Pubitemid 46456902)
23. Krishna G, Sansone-Parsons A, Kantesaria B: Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin 2007, 23:1415-1422. (Pubitemid 46998449)
24. Krishna G, Moton A, Ma L, et al.: Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009, 31:286-298.
25. Sansone-Parsons A, Krishna G, Martinho M, et al.: Effect of oral posaconazole on pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007, 27:825-834. (Pubitemid 46849426)
26. Krishna G, Moton A, Ma L, et al.: Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr 2009, 51:437-444.
27. Sporanox (itraconazole) capsules [package insert]. Titusville, NJ: Janssen; 2008.
28. Kaukonen KM, Olkkola KT, Neuvonen PJ: Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther 1997, 62:510-517. (Pubitemid 28214928)
29. Jalava KM, Partanen J, Neuvonen PJ: Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997, 19:609-613. (Pubitemid 28046984)
30. Marr KA, Leisenring W, Crippa F, et al.: Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004, 103:1557-1559. (Pubitemid 38168678)
31. Varhe A, Olkkola KT, Neuvonen PJ: Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994, 56:601-607. (Pubitemid 124006567)
32. Ahonen J, Olkkola KT, Neuvonen PJ: Effects of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 1995, 40:270-272.
33. Bruggemann R, Alffenaar JW, Blijlevens NM, et al.: Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009, 48:1441-1458. This article provides the most current and complete review of azole drug interactions available. To assist practitioners in assessing the relevance of the interaction, the authors include a detailed table that ranks drug interactions by potential clinical significance.
34. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ: The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998, 54:53-58. (Pubitemid 28189400)
35. Neuvonen PJ, Jalava KM: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996, 60:54-61. (Pubitemid 26279221)
36. Kivisto KT, Kantola T, Neuvonen PJ: Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998, 46:49-53. (Pubitemid 28308424)
37. Kantola T, Kivisto KT, Neuvonen PJ: Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998, 64:58-65. (Pubitemid 28377331)
38. Clinical Pharmacology. Drug Interaction Report. http:// clinicalpharmacology-ip.com/Forms/Reports/intereport.aspx. Accessed January 15, 2010.
39. Sugar AM: Use of amphotericin B with azole antifungal drugs: What are we doing? Antimicrob Agents Chemother 1995, 39:1907-1912.
40. Rex JH, Pappas PG, Karchmer AW, et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36:1221-1228. (Pubitemid 36629929)
41. Denning DW: Echinocandins: a new class of antifungal. J Antimicrob Chemother 2002, 49(6):889-891.
42. Sucher A, Chahine E, Balcer H: Echinocandins: the newest class of antifungals. Ann Pharmacother 2009, 43:1647-1657. This paper provides a current review of the echinocandin class. Drug interactions of the class are briefly discussed and placed in perspective.
43. Cancidas [package insert]. Whitehouse Station, NJ: Merck; 2010.
44. Herbert M, Smith H, Marbury T: Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005, 45:1145-1152. (Pubitemid 41361914)
45. Mycamine [package insert]. Deerfield, IL: Astellas Pharma US; 2005.
46. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm 2006, 63(18):1697-1703.
47. Dowell J, Stogniew M, Krause D, et al.: Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005, 45:227-233. (Pubitemid 40490447)
48. Eraxis [package insert]. New York, NY: Pfizer; 2006.
49. Cada D, Levien T, Baker D: Anidulafungin. Hosp Pharm 2006, 41:669-680.
50. Wood N, Tan K, Purkins L, et al.: Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003, 56(Suppl 1):56-61. (Pubitemid 37491735)